Showing results (1271-1280 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 17, 2021
Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitorsAntian Gao, Xiao Pan, Xudong Yang, et al.
Investigational New Drugs|February 24, 2021
A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanomaSotiris Kyriakou, William Cheung, Theodora Mantso, et al.
Investigational New Drugs|June 1, 1988
Alterations in human circulating and bone marrow mononuclear cell polyamine levels in hematologic malignancies as a consequence of difluoromethylornithine administrationA M Maddox, E J Freireich, M J Keating, et al.
Investigational New Drugs|August 22, 2019
Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cellsArusha Modi, Meenakshi Singh, Gopichand Gutti, et al.
Investigational New Drugs|September 5, 2019
Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cellsKatrin Manda, Tina Präkelt, Tonja Schröder, et al.
Investigational New Drugs|November 8, 2018
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancerPedro C Barata, Matthew Cooney, Prateek Mendiratta, et al.
Investigational New Drugs|August 26, 2019
Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell linesMaximilian Hochmair, Barbara Rath, Lukas Klameth, et al.
Investigational New Drugs|August 5, 2019
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancerNikita M Volkov, Grigoriy A Yanus, Alexandr O Ivantsov, et al.
Investigational New Drugs|July 31, 2019
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaW Larry Gluck, Mrinal M Gounder, Richard Frank, et al.
Investigational New Drugs|March 7, 2014
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinomaYoshihiko Ooka, Tetsuhiro Chiba, Sadahisa Ogasawara, et al.
Pageof 372